Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 2/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.37 |
| ▸ | RARG | P13631 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 3/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20134743 | 1.00 | LMNA (0.48) | LMNAMEN1KMT2ATNKSRARB | |
| SCHEMBL20134909 | 0.84 | LMNA (0.49) | LMNAMEN1KMT2ATNKSRARB | |
| SCHEMBL20134995 | 0.84 | LMNA (0.49) | LMNAMEN1KMT2ATNKS | |
| SCHEMBL20135251 | 0.83 | LMNA (0.46) | LMNAMEN1KMT2ATNKS | |
| SCHEMBL20135103 | 0.83 | LMNA (0.48) | LMNAMEN1KMT2ATNKSRXRA | |
| SCHEMBL20135060 | 0.80 | MMP14 (0.45) | RARBRARARARGRXRARXRB | |
| SCHEMBL20135629 | 0.80 | AKR1B1 (0.35) | RARBHCAR3HCAR2RARARARG | |
| SCHEMBL20134959 | 0.79 | LMNA (0.52) | LMNAMEN1KMT2ATNKS | |
| SCHEMBL20134957 | 0.79 | LMNA (0.52) | LMNAMEN1KMT2ATNKS | |
| SCHEMBL29688463 | 0.79 | LMNA (0.52) | LMNAMEN1KMT2ATNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922347-B | Novel imide derivatives and their use as pharmaceuticals | 田边三菱制药株式会社 | 2022-06-28 | — | — | CN | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | LMNA 4264/4885MEN1 3735/4885KMT2A 2568/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | LMNA 4113/4885MEN1 2913/4885KMT2A 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.